Every regulatory and clinical statement on this site traces to an official source. Below, each is linked to the U.S. Food & Drug Administration, the Centers for Disease Control and Prevention, the United States Pharmacopeia, the National Institutes of Health, or the peer-reviewed study it comes from.
Compounded medications are prepared for an individual patient by a state-licensed compounding pharmacy pursuant to a prescription. They are not FDA-approved finished drug products, and the FDA does not review compounded medications for safety, effectiveness, or quality.
A medication "compounded in the USA, to a real standard" means it is prepared by a state-licensed pharmacy working to the enforceable United States Pharmacopeia (USP) standards for compounding: General Chapter <795> for nonsterile preparations and General Chapter <797> for sterile preparations, which set the personnel, facility, component, quality-assurance and beyond-use-dating requirements those pharmacies operate under.
USP General Chapter <795>: Pharmaceutical Compounding, Nonsterile Preparations ↗ · USP General Chapter <797>: Sterile Preparations ↗
Refrigerated injectable medications such as semaglutide are stored at 2°C to 8°C (36°F to 46°F), protected from light, and not frozen, per FDA-approved product labeling.
NIH DailyMed: WEGOVY (semaglutide) FDA label: Storage and Handling ↗
Once a multi-dose vial has been punctured, CDC guidance is to date it and discard it within 28 days unless the manufacturer specifies a different date for the opened vial; USP General Chapter <797> sets the underlying beyond-use-date standards for sterile preparations. This is the basis for Thrive's 28-day practice: one bill for one vial, with a fresh vial sent each time one is needed.
CDC: Single-dose or multi-dose? Not all vials are created equal (PDF) ↗ · USP General Chapter <797>: Sterile Preparations ↗
Compounded semaglutide and tirzepatide are not FDA-approved and are not generic equivalents of, or interchangeable with, the brand-name products (Ozempic, Wegovy, Mounjaro, Zepbound), which are the only FDA-approved semaglutide and tirzepatide medicines.
FDA: Concerns with unapproved GLP-1 drugs used for weight loss ↗
GLP-1 medicines in the semaglutide class are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Acute pancreatitis has been observed with GLP-1 receptor agonists, and the medicine should be discontinued in patients who become pregnant while using it for weight reduction. A licensed provider screens for these and other factors during intake.
NIH DailyMed: WEGOVY (semaglutide) FDA label: Contraindications & Warnings ↗
The most common adverse reactions reported with semaglutide are gastrointestinal, including nausea, diarrhea, vomiting, and constipation.
NIH DailyMed: WEGOVY (semaglutide) FDA label: Adverse Reactions ↗
Treatment is started at a low dose and stepped up over several weeks rather than begun at a full dose: semaglutide is initiated at 0.25 mg once weekly for 4 weeks and titrated every 4 weeks toward a maintenance dose. Because tolerability is dose-related, the labeling directs that if a patient does not tolerate a dose during escalation, the increase may be delayed — which is why a provider can slow the titration.
NIH DailyMed: WEGOVY (semaglutide) FDA label: Dosage & Administration ↗
These medications are given once weekly by subcutaneous injection in the abdomen, thigh, or upper arm, with the injection site rotated with each dose.
NIH DailyMed: WEGOVY (semaglutide) FDA label: Dosage & Administration ↗
Patients are advised to contact their provider promptly about severe or persistent abdominal pain, ongoing vomiting, or signs of dehydration. Postmarketing reports of acute kidney injury have occurred in patients treated with semaglutide, the majority in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea; the labeling directs monitoring of renal function in patients reporting reactions that could lead to volume depletion.
NIH DailyMed: WEGOVY (semaglutide) FDA label: Warnings & Precautions ↗
A needle and syringe are used one time only and are never reused or shared — CDC states the rule plainly as "One Needle, One Syringe, Only One Time." Used needles and other sharps are placed immediately in an FDA-cleared sharps disposal container rather than in household trash.
CDC: Preventing Unsafe Injection Practices ↗ · FDA: Sharps Disposal Containers ↗
Trial results referenced on the product pages come from studies of the branded, FDA-approved medicines. Compounded versions share the active ingredient but are not the identical product and have not been individually studied.
Semaglutide weight-loss results (STEP 1 trial).
Semaglutide cardiovascular-event reduction in obesity without diabetes (SELECT trial).
Tirzepatide is a dual GIP / GLP-1 receptor agonist: it binds the GIP receptor with affinity comparable to native GIP, while its GLP-1-receptor affinity is roughly 18–20× weaker than native GLP-1; its gastric-slowing ("feel full longer") effect is driven by GLP-1-receptor agonism, not GIP.
In SURMOUNT-1, tirzepatide's weight loss was approximately 74% fat mass / 26% lean mass (versus 75% / 25% on placebo), preserving the fat-to-lean loss ratio.
GLP-1 receptor agonists such as semaglutide work with the body's appetite signals: enhancing satiety, slowing gastric emptying, and reducing hunger and energy intake.
GLP-1 analogues, appetite & gastric emptying: systematic review, PMC9987242 ↗
Patients on GLP-1 medications frequently report a reduction in "food noise," persistent, intrusive thoughts about food; this patient-reported effect is beginning to be documented in early research.
About this page. The facts behind every statement on this site come from the official sources linked above. The wording on our pages is our own; nothing is copied from another company. This page is provided for transparency and is not a substitute for the full prescribing information or for medical advice. Availability and regulatory status of compounded medications can change; a licensed provider makes all prescribing decisions.